With ongoing advancements in prostate cancer diagnosis, targeted biopsies guided by mpMRI or Prostate Specific Membrane Antigen (PSMA) PET/CT have steadily increased the detection rate of prostate cacner, reducing unnecessary biopsies [24, 25]. The gene discussed is FOLH1; the disease is prostate carcinoma.